Key result
ADRB1 Ser49Gly and Arg389Gly polymorphisms were not associated with essential hypertension, though ADRB1 mRNA expression differed between hypertensives and controls based on Ser49Gly variants.
Why the study?
Do ADRB1 Ser49Gly and Arg389Gly polymorphisms affect ADRB1 mRNA expression and susceptibility to essential hypertension in a South Indian population?
Case-Control (n=616)
Do ADRB1 Ser49Gly and Arg389Gly polymorphisms affect ADRB1 mRNA expression and susceptibility to essential hypertension in a South Indian population?
ADRB1 Ser49Gly polymorphisms influence ADRB1 mRNA expression levels but do not appear to confer genetic risk for essential hypertension in a South Indian population.
Answers are grounded in this paper and cite their sources.
ADRB1 SNPs should not inform hypertension risk assessment; hypothesis-generating for Ser49Gly-linked mRNA expression and β-blocker response in South Indians.
BACKGROUND: β1-Adrenoreceptor (ADRB1) genetic polymorphisms are widely studied for susceptibility to many cardiovascular diseases such as essential hypertension. However, the mRNA expression of ADRB1 is rarely studied. METHODS: A case-control pilot study with 292 hypertensives and 324 controls was designed to evaluate the role of the Ser49Gly and Arg389Gly, which are commonly studied single nucleotide polymorphisms (SNP), in the mRNA levels of ADRB1, in conjunction with its genetic predisposition to essential hypertension. RESULTS: Differential expression of ADRB1 mRNA was seen between hypertensives and controls (p<0.01) based on genetic variants of Ser49Gly. Among hypertensive subjects, Ser49Ser and Gly49Gly were highly expressed in comparison to Ser49Gly (p<0.05 and p<0.01, respectively), whereas genetic variants of Arg389Gly did not demonstrate any such variations. We found no association between the ADRB1 SNPs viz., Ser49Gly and Arg389Gly and essential hypertension. CONCLUSIONS: The increased mRNA levels of Gly49Gly may indicate a plausible role in the interindividual variations in drug response. Further, ADRB1 polymorphisms did not contribute to the genetic risk of essential hypertension. Studies with larger sample size are warranted to confirm these observations in the South Indian population.
No takes yet. Share an insight, caveat, or question.
Varakantham et al. (2018) conducted a case-control in essential hypertension (n=616). ADRB1 Ser49Gly and Arg389Gly polymorphisms vs. Controls (normotensives) was evaluated on ADRB1 mRNA expression and association with essential hypertension (p=<0.01). ADRB1 Ser49Gly and Arg389Gly polymorphisms were not associated with essential hypertension, though ADRB1 mRNA expression differed between hypertensives and controls based on Ser49Gly variants.
Synapse has enriched 10 related papers. Consider them for comparative context: